Bridge Neurotech Raises $13.5 Million for Ultrasound-Based Non-Invasive BCI

Bridge Neurotech has raised $13.5 million to develop a non-invasive brain-computer interface that uses ultrasound instead of electrical recording to detect neural activity. The company announced the round this week, positioning acoustic sensing as an alternative to both scalp EEG and the implanted electrodes used in today's high-bandwidth BCIs.

The headline number matters for clinical neurophysiology readers: $13.5 million is a seed-to-early-stage commitment, not a commercialization war chest. It funds continued development of a technology that has not yet produced an FDA-cleared device. Everything in the announcement is investigational.

Why ultrasound instead of EEG or implanted electrodes?

Non-invasive BCIs to date have leaned on scalp EEG, which offers millisecond timing but poor spatial resolution because the skull and scalp blur the electrical signal. Implanted arrays and ECoG deliver far higher signal fidelity, at the cost of neurosurgery and the infection or hardware-failure risks that come with craniotomy.

Ultrasound occupies a different point on that trade-off curve. Acoustic waves pass through bone with far less attenuation than electrical signals, and researchers have used the approach — often called functional ultrasound — to image blood-flow dynamics tied to neural activity with spatial resolution on the order of small cortical columns in animal work. Bridge Neurotech is betting the modality can carry a wearable, non-invasive BCI.

The key caveat for reading-room audiences: functional ultrasound BCI performance in freely moving humans remains largely unproven. Most of the strongest published evidence comes from animal models. The company has not disclosed clinical results, a regulatory timeline, or an FDA pathway in this announcement.

What the funding actually buys

According to the announcement, the $13.5 million will support continued development of the ultrasound-based interface. The company's stated goal is a non-invasive system that avoids surgery entirely — the defining constraint that has kept high-performance BCIs confined to research volunteers and a small number of implanted trial participants.

For clinical neurophysiology teams, the practical questions will come later:

• Can an acoustic BCI resolve signal at the level needed for communication or motor decoding in humans?
• Will the headset-scale form factor hold up outside the lab?
• Which FDA pathway — 510(k), De Novo, or an IDE for first-in-human trials — will the company pursue?

None of those questions has a disclosed answer yet.

The competitive context

Bridge Neurotech enters a field where the invasive players dominate headlines: Neuralink, Paradromics, and Blackrock Neurotech have all implanted devices in human participants, while non-invasive entrants have mostly stayed within EEG- or MEG-based research systems. An ultrasound-based approach would sidestep both camps' core limitation — surgery on one side, low bandwidth on the other.

That is the promise. The burden of proof sits with human data, which this funding round is presumably meant to generate. For now, clinicians and BCI researchers should treat Bridge Neurotech as an early-stage bet on an alternative recording physics, not a near-term tool for the monitoring unit or lab bench.

The next milestone worth watching is a first-in-human demonstration: without human recordings, the modality's decoding performance remains an open question that no amount of venture funding can answer.